Home Cart Sign in  
Chemical Structure| 1644060-37-6 Chemical Structure| 1644060-37-6

Structure of Fumarate hydratase-IN-1
CAS No.: 1644060-37-6

Chemical Structure| 1644060-37-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fumarate hydratase-IN-1, an enzyme of the TCA cycle.

Synonyms: Fumarate hydratase-IN-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fumarate hydratase-IN-1

CAS No. :1644060-37-6
Formula : C27H30N2O4
M.W : 446.54
SMILES Code : O=C(OCC)[C@]1([C@H](CC(NC)=O)C2=O)C(N2CC(C=C3)=CC=C3C4=CC=CC=C4)=CCCC1
Synonyms :
Fumarate hydratase-IN-1
MDL No. :MFCD30187520
InChI Key :VFGLXHHVYNTCPD-AJTFRIOCSA-N
Pubchem ID :121230973

Safety of Fumarate hydratase-IN-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BMDMs 25 μM To test whether L-malate inhibits inflaμMation through the secondary accumulation of fumarate, FHIn1 was used, and it did not influence the anti-inflaμMatory effect of L-malate PMC11683149
MV411 cells 3 μM Used to validate the specificity of enzyme activity assay PMC11183053
BMDMs 10 or 20 μM 3 h To evaluate the effects of FHIN1 on bioenergetics, metabolites, and mitochondrial membrane potential in BMDMs. Results showed that FHIN1 treatment reduced ATP/ADP and phosphocreatine/creatine ratios, increased mitochondrial membrane potential, and led to TCA cycle metabolite rewiring. PMC5570934

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice LPS-induced inflammation model intraperitoneal injection 0.2 mg/kg body weight per day once daily for 4 weeks To evaluate the effect of FHIN1 on IFN-β release in the LPS-induced inflammation model. Results showed that FHIN1 increased LPS-induced IFN-β release, while DMF had no effect. PMC10411300

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.24mL

0.45mL

0.22mL

11.20mL

2.24mL

1.12mL

22.39mL

4.48mL

2.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories